IL317220A - Using Vibravir to treat overactive bladder - Google Patents

Using Vibravir to treat overactive bladder

Info

Publication number
IL317220A
IL317220A IL317220A IL31722024A IL317220A IL 317220 A IL317220 A IL 317220A IL 317220 A IL317220 A IL 317220A IL 31722024 A IL31722024 A IL 31722024A IL 317220 A IL317220 A IL 317220A
Authority
IL
Israel
Prior art keywords
vibegron
dose
subjects
subject
weeks
Prior art date
Application number
IL317220A
Other languages
English (en)
Hebrew (he)
Original Assignee
Urovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62815097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL317220(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Urovant Sciences Gmbh filed Critical Urovant Sciences Gmbh
Publication of IL317220A publication Critical patent/IL317220A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL317220A 2017-06-06 2018-06-06 Using Vibravir to treat overactive bladder IL317220A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762515996P 2017-06-06 2017-06-06
US201862635146P 2018-02-26 2018-02-26
US201862637961P 2018-03-02 2018-03-02
PCT/IB2018/054069 WO2018224989A1 (en) 2017-06-06 2018-06-06 Use of vibegron to treat overactive bladder

Publications (1)

Publication Number Publication Date
IL317220A true IL317220A (en) 2025-01-01

Family

ID=62815097

Family Applications (2)

Application Number Title Priority Date Filing Date
IL317220A IL317220A (en) 2017-06-06 2018-06-06 Using Vibravir to treat overactive bladder
IL271164A IL271164A (en) 2017-06-06 2019-12-04 Use of vibegron to treat overactive bladder

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL271164A IL271164A (en) 2017-06-06 2019-12-04 Use of vibegron to treat overactive bladder

Country Status (14)

Country Link
US (1) US12102638B2 (enExample)
EP (2) EP3634420A1 (enExample)
JP (3) JP7682605B2 (enExample)
KR (2) KR20200012949A (enExample)
CN (3) CN117695287A (enExample)
AU (2) AU2018282104B2 (enExample)
BR (1) BR112019025636A2 (enExample)
CA (1) CA3064989A1 (enExample)
CL (1) CL2019003533A1 (enExample)
IL (2) IL317220A (enExample)
MX (1) MX2022015629A (enExample)
PH (1) PH12019502651A1 (enExample)
WO (1) WO2018224989A1 (enExample)
ZA (1) ZA202000028B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3085745A1 (en) * 2017-12-21 2019-06-27 Kyorin Pharmaceutical Co., Ltd. An agent for treating nocturnal pollakiuria
EP3890743A1 (en) * 2018-12-05 2021-10-13 Urovant Sciences GmbH Vibegron for the treatment of overactive bladder symptoms
JP2022524576A (ja) * 2019-03-18 2022-05-09 ウロバント サイエンシズ ゲーエムベーハー 過活動膀胱を処置するためのビベグロンの使用
DE102020124101A1 (de) 2020-02-04 2021-08-05 Samsung Electronics Co., Ltd. Elektronische vorrichtung mit einer speichervorrichtung und trainingsverfahren
TW202239412A (zh) * 2020-12-22 2022-10-16 瑞士商優洛凡特科學公司 使用維貝格隆（ｖｉｂｅｇｒｏｎ）並監測地高辛（ｄｉｇｏｘｉｎ）以治療膀胱過動症的方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1028111T3 (da) 1997-10-17 2004-09-20 Yamanouchi Pharma Co Ltd Amidderivater eller salte heraf
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
DOP2003000587A (es) 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
AU2003284700B2 (en) 2002-11-07 2009-05-28 Astellas Pharma Inc. Remedy for overactive bladder comprising acetic acid anlide derivatives as the active ingredient
ES2309513T3 (es) 2003-05-05 2008-12-16 Kissei Pharmaceutical Co., Ltd. Uso de derivados de acido fenoxiacetico para tratar vejiga hiperactiva.
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
WO2008128968A1 (en) 2007-04-19 2008-10-30 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
CN101855342B (zh) 2007-09-13 2013-07-10 科德克希思公司 用于还原苯乙酮的酮还原酶多肽
WO2009057685A1 (ja) 2007-11-02 2009-05-07 Astellas Pharma Inc. 過活動膀胱治療用医薬組成物
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
WO2010025085A2 (en) 2008-08-29 2010-03-04 Codexis, Inc. Ketoreductase polypeptides for the stereoselective production of (4s)-3[(5s)-5(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
BR112012007829A2 (pt) 2009-10-07 2015-09-22 Merck Sharp & Dohme método para tratar bexiga hiperativa, e, composição farmacêutica.
JP5812500B2 (ja) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ３アドレナリン作動性受容体アゴニスト
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
PE20131341A1 (es) 2010-08-03 2013-12-07 Altherx Inc Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva
KR20200003245A (ko) 2011-10-14 2020-01-08 어레이 바이오파마 인크. 선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
EP2770996B1 (en) 2011-10-27 2016-09-28 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
WO2013074650A1 (en) 2011-11-18 2013-05-23 Codexis, Inc. Biocatalysts for the preparation of hydroxy substituted carbamates
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
LT2968269T (lt) 2013-03-15 2019-10-25 Merck Sharp & Dohme Beta 3 agonistų ir tarpinių junginių gamybos būdas
KR20170086659A (ko) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
PL3365321T3 (pl) 2015-10-23 2024-03-25 B3Ar Therapeutics, Inc. Jon obojnaczy solabegronu i jego zastosowania
EP3463312A4 (en) 2016-06-03 2020-02-05 Velicept Therapeutics, Inc. DOSAGE DIAGRAMS FOR BETA-3 ADRENERGIC RECEPTOR AGONISTS AND ANTI-MUSCARIN AGENTS FOR THE TREATMENT AND PREVENTION OF LOWER URINARY SYMPTOMS AND VESICAL HYPERACTIVITY
US20170348263A1 (en) 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
US20210077496A1 (en) 2017-06-06 2021-03-18 Urovant Sciences Gmbh Dosing of vibegron for treatment of overactive bladder
CA3085745A1 (en) 2017-12-21 2019-06-27 Kyorin Pharmaceutical Co., Ltd. An agent for treating nocturnal pollakiuria
TW202015692A (zh) 2018-05-23 2020-05-01 瑞士商優洛凡特科學公司 維貝格龍（ｖｉｂｅｇｒｏｎ）於治療與腸躁症候群相關之疼痛之用途
EP3890743A1 (en) 2018-12-05 2021-10-13 Urovant Sciences GmbH Vibegron for the treatment of overactive bladder symptoms
JP2022524576A (ja) 2019-03-18 2022-05-09 ウロバント サイエンシズ ゲーエムベーハー 過活動膀胱を処置するためのビベグロンの使用
TW202239412A (zh) 2020-12-22 2022-10-16 瑞士商優洛凡特科學公司 使用維貝格隆（ｖｉｂｅｇｒｏｎ）並監測地高辛（ｄｉｇｏｘｉｎ）以治療膀胱過動症的方法
US20240148735A1 (en) 2021-02-16 2024-05-09 Urovant Sciences Gmbh Methods of treating heart failure with vibegron

Also Published As

Publication number Publication date
PH12019502651A1 (en) 2020-06-08
EP3634420A1 (en) 2020-04-15
AU2024204591A1 (en) 2024-07-18
CN117695287A (zh) 2024-03-15
KR20250099259A (ko) 2025-07-01
JP2023071826A (ja) 2023-05-23
AU2018282104A1 (en) 2019-12-12
JP7682605B2 (ja) 2025-05-26
WO2018224989A1 (en) 2018-12-13
BR112019025636A2 (pt) 2020-08-25
EP4410295A3 (en) 2024-10-16
EP4410295A2 (en) 2024-08-07
KR20200012949A (ko) 2020-02-05
CA3064989A1 (en) 2018-12-13
MX2022015629A (es) 2023-01-11
JP2020522560A (ja) 2020-07-30
CN110869022A (zh) 2020-03-06
CN117695286A (zh) 2024-03-15
CL2019003533A1 (es) 2020-06-26
IL271164A (en) 2020-01-30
ZA202000028B (en) 2025-09-25
US20210077495A1 (en) 2021-03-18
US12102638B2 (en) 2024-10-01
JP2025063196A (ja) 2025-04-15
AU2018282104B2 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
US20230218624A1 (en) Dosing of vibegron for treatment of overactive bladder
AU2024204591A1 (en) Use of vibegron to treat overactive bladder
US20090068290A1 (en) Bifeprunox doses for treating schizophrenia
WO2008025781A1 (en) Bifeprunox doses for treating schizophrenia
AU2019393372B2 (en) Vibegron for the treatment of overactive bladder symptoms
CA3098536A1 (en) Use of vibegron to treat pain associated with irritable bowel syndrome
HK40114255A (en) Use of vibegron to treat overactive bladder
EA045454B1 (ru) Применение вибегрона для лечения гиперактивного мочевого пузыря
CN101573117A (zh) 用于治疗精神分裂症的联苯芦诺剂量